This article is more than 5 years old. Information may no longer be current.
Trial of quisinostat in ovarian cancer meets primary endpoints
Click Here to Manage Email Alerts
A phase 2 trial designed to assess the safety and efficacy of quisinostat in combination with paclitaxel and carboplatin for treatment of platinum-resistant ovarian cancer met all of its primary endpoints, according to its manufacturer.
Quisinostat — which NewVac licensed from Janssen Pharmaceutica NV — is a novel selective oral histone deacetylase (HDAC) inhibitor. The agent, which selectively accumulates in target tissues, helps to restore sensitivity to chemotherapy in platinum-resistant cases.
The phase 2 trial included patients with metastatic or locally advanced epithelial ovarian cancer — primarily peritoneal or fallopian tube carcinoma — resistant to first-line platinum and paclitaxel-based chemotherapy.
Treatment was administered in 21-day cycles for up to six cycles. Researchers performed a safety follow-up 4 weeks after the final administration of therapy, as well as post-treatment follow-up to assess PFS, time to disease progression and OS.
Complete results of the multicenter, open-label study will be presented at a research meeting later this year, according to a NewVac-issued press release.